The U.S. Food and Drug Administration (FDA) revised the label for Metformin hydrochloride on 2026-05-11, adding a new boxed warning concerning the risk of lactic acidosis. This warning highlights postmarketing cases of metformin-associated lactic acidosis that have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias.
Background
Metformin hydrochloride is a widely prescribed medication and a cornerstone therapy for the management of Type 2 Diabetes. It is often recommended as a first-line treatment and can be used alone or in combination with other antidiabetic agents, including SGLT2 inhibitors such as canagliflozin, dapagliflozin, and empagliflozin. Lactic acidosis is a serious metabolic complication characterized by the accumulation of lactate in the blood, which can be life-threatening.
What this means
The addition of a boxed warning to the Metformin hydrochloride label represents a critical safety update, emphasizing the severe and potentially fatal risk of lactic acidosis. This warning serves to heighten awareness among clinicians and patients regarding the serious nature of this adverse event. The FDA's update specifically notes that postmarketing cases of metformin-associated lactic acidosis have resulted in severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of this condition is often subtle, making early recognition challenging but crucial. Clinicians are advised to be vigilant for any signs or symptoms, which may include malaise, myalgias, respiratory distress, somnolence, and abdominal distress. Prompt diagnosis and management are essential, as metformin-associated lactic acidosis requires immediate medical attention. This update reinforces the need for careful patient selection, ongoing monitoring, and thorough patient education regarding the risk factors and symptoms of lactic acidosis.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA). The updated label for Metformin hydrochloride, reflecting the new boxed warning, became effective on 2026-05-11 and is accessible via dailymed.nlm.nih.gov.